The specificity of drug therapy in individuals and races has promoted the development and improvement of pharmacogenomics and precision medicine. While there is a few cognition on the minorities in China, especially in Lisu nationality from the Yunnan Province. Therefore, we performed the research to improve the role of pharmacogenomics in the Lisu population from the Yunnan province of China.
Materials and Methods
In our study, 54 variants of very important pharmacogenes (VIPs) selected from the PharmGKB database were genotyped in 199 unrelated and healthy Lisu adults from the Yunnan province of China, and then, genotyping data wtih χ2 test were analyzed.
We compared our date with those of other 26 populations from the 1000 Genomes Project, and acquired that the Lisu ethnicity is similar with the CDX(Chinese Dai in Xishuangbanna, China) and CHS(Southern Han Chinese, China). Furthermore, rs776746 (CYP3A5), rs1805123 (KCNH2), rs4291 (ACE), rs1051298 (SLC19A1) and rs1065852 (CYP2D6) were deemed as the most varying loci. The MAF of “G” at rs1805123 (KCNH2) in the Lisu population was the largest with the value of 51.0%.
Our results show that there are significant differences in SNP (single nucleotide polymorphism) loci, supplementing the pharmacogenomic information of the Lisu population in Yunnan province, China, and can provide a theoretical basis for individualized medication in the future.